---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Long-term morbidity"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Long-term morbidity. Topics: Legal blindness: share of U.S. legal blindness attributed to geographic atrophy, Legal blindness: progression to blindness in U.S. Medicare Advantage claims, Legal blindness and loss of driving eligibility in bilateral geographic atrophy in U.K. practice, Loss of driving-level acuity and progression to 20/200 or worse over 24 months in the IRIS Registry, and 7 further topics. 11 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Legal blindness: share of U.S. legal blindness attributed to geographic atrophy

> “Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and is responsible for approximately 20% of legal blindness in the United States.”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.7-2"></a>

### Legal blindness: progression to blindness in U.S. Medicare Advantage claims

> “Among individuals with GA without SFI at index, 173 (3.6%) developed irreversible blindness, compared to 312 (6.6%) of those with SFI, and 51 (0.5%) individuals without GA.”
> “Both diagnosis of GA without SFI (hazard ratio [HR] [CI] = 6.77 [4.98-9.35], P < 0.001) and diagnosis of GA with SFI (HR [CI] = 12.59 [9.43-17.16], P < 0.001) were strongly associated with increased risk of developing irreversible blindness.”
> “Irreversible blindness was defined as any patient with a diagnosis code for blindness (ICD-10-CM = H54.0, H54.1, H54.4, H54.8) in the claims database.”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.7-3"></a>

### Legal blindness and loss of driving eligibility in bilateral geographic atrophy in U.K. practice

> “Progression to blindness (visual acuity [VA] <20 letters or Snellen 3/60 in the better-seeing eye), driving ineligibility (VA ≤70 letters or Snellen 6/12 in the better-seeing eye)”
> “At first record of GA, 7.1% had a VA in the better-seeing eye equal to or lower than the cutoff for blindness registration and 71.1% had a VA that would have rendered them ineligible to drive. Over time, 16% became legally blind (median time to outcome, 6.2 years) and 66.7% became ineligible to drive (median time to outcome, 1.6 years).”

Source: [Chakravarthy et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29366564/)

<a id="topic-2.2.1.7-4"></a>

### Loss of driving-level acuity and progression to 20/200 or worse over 24 months in the IRIS Registry

> “Among study eyes with VA of 20/40 or better at baseline, the rates of decline were similar in both cohorts, with 30.2% in the GA:GA cohort and 30.0% in the GA:nAMD cohort progressing to VA worse than 20/40 at 24 months.”
> “Among study eyes with VA worse than 20/40 and better than 20/200 at index, 29.7% of the GA:GA and 27.6% of the GA:nAMD cohorts progressed to VA 20/200 or worse at 24 months.”

Source: [Rahimy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232896/)

<a id="topic-2.2.1.7-5"></a>

### Visual impairment in eyes with geographic atrophy in European population-based studies

> “Before 2006, 54.2% of eyes with GA were visually impaired, and 79.8% of eyes suffering from CNV were visually impaired. From 2006 onward, the proportion of visually impaired eyes remained the same for GA (47.6%; P = 0.40), but dropped to 66.2% (P = 0.026) for CNV (Fig 7A).”

Source: [Colijn et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5755466/)

<a id="topic-2.2.1.7-6"></a>

### Blindness and vision impairment due to AMD worldwide, 1990 to 2021 (all AMD subtypes combined)

> “Cases of moderate vision loss rose from 2·13 million (95% UI 1·64–2·76) in 1990 to 5·39 million (4·18–7·00) in 2021, severe vision loss increased from 0·39 million (0·28–0·51) to 0·79 million (0·58–1·03), and blindness rose from 1·12 million (0·84–1·47) to 1·88 million (1·41–2·46).”

Source: [GBD 2021 Global AMD Collaborators (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12208786/)

<a id="topic-2.2.1.7-7"></a>

### Falls and fractures in U.S. claims databases

> “Risks of falls (RR 1.16–1.36) and fractures (RR 1.17–1.29) in the 4 years following the index date were higher in patients with GA compared with controls. Patients with bilateral GA and subfoveal involvement had the most pronounced increase in risk of falls (RR 1.42–1.49) and fractures (RR 1.33–1.45).”

Source: [Hu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006262/)

<a id="topic-2.2.1.7-8"></a>

### Injurious falls in U.S. Medicare Advantage claims by geographic atrophy and blindness status

> “Although the overall rate of all-cause injurious falls per 100 person-years did not differ meaningfully between patients with GA only and those with no GA (P=0.122), patients with GA only had 1.24 (95% CI: 1.05, 1.45) times more all-cause falls with head injuries and 0.67 (95% CI: 0.51, 0.89) times fewer all-cause falls with joint dislocations per 100 person-years compared to patients with no GA (both P<0.05).”
> “Patients with GA + B had higher rates of both all-cause and ophthalmic condition-related injurious falls, with 1.69 (95% CI: 1.29, 2.23) times more all-cause injurious falls per 100 person-years and 5.94 (95% CI: 3.40, 10.36) times more ophthalmic condition-related injurious falls per 100 person-years than patients with GA only (both P<0.05).”

Source: [Sarda et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559221/)

<a id="topic-2.2.1.7-9"></a>

### Fall-related injuries in a matched U.S. Medicare Advantage cohort

> “No statistically significant differences were observed in the IRs for fall-related injuries and anxiety disorders between the matched cohorts (Table 2).”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.7-10"></a>

### Depression: new-onset depression in a matched U.S. Medicare Advantage cohort

> “In this study, the prevalence of depression at baseline was observed in one-fifth or more of the study sample (ranged 19.9%-22.6%). Furthermore, the incidence of new onset depression during the follow-up period was greater in GA cohort than non-GA cohort (86.6 vs 77.3 per 1,000 person years, P = 0.004).”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.7-11"></a>

### Institutionalization: nursing home or assisted living admissions in U.S. claims databases

> “Compared to controls, patients with GA also had an increased risk for hospitalization (RR 1.18–1.27), emergency department visits (RR 1.18–1.21), nursing home or assisted living admissions (RR 1.06–1.28), and outpatient visits (RR 1.05–1.08).”
> “In addition, the risk of ED visits was 18% to 21% (RR [95% CI] 1.18 [1.11–1.25] to 1.21 [1.18–1.23]) higher (Fig. S2 in the Supplementary Material), and the risk of nursing home or assisted living facility admissions was 6% to 28% (RR [95% CI] 1.06 [0.99–1.13] to 1.28 [1.24–1.31]) higher”

Source: [Hu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006262/)

Additional sources: [Danzig et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38719191/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
